To assess the feasibility of donor-derived interferon (IFN)-γ positive select-ed virus-specific T-cells using the cytokine capture system® (CCS) and the safety of subsequent infusion in recipients of hematopoietic stem cell transplantation (HSCT) with treatment refractory post-transplant viral infections. The CCS has already been successfully used in clinical studies in Germany and United Kingdom (UK).
Adults > 18 years of age
Undergone allogeneic HSCT
Written informed consent
Antiviral treatment with cidofovir for at least 7 days
graft-versus-host disease (GVHD) > grade 2 at the time point of planned infusion
Known allergy to iron-dextran or murine antibodies
Single group
IFN-γ positive selected T-cells
Biological/VaccineLevel of enriched IFN-γ+ T-cells
Treatment efficacy
Treatment efficacy defined as reduction of virus load, in vivo expansion of antigen-specific T cells in peripheral blood as well as reduction of clinical signs of specific viral infection
Click on the lead sponsor to view all of their trials.
